Elsevier

Respiratory Medicine

Volume 88, Issue 7, August 1994, Pages 531-535
Respiratory Medicine

Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis

https://doi.org/10.1016/S0954-6111(05)80337-3Get rights and content

Oral N-acetylcysteine (NAC) exerts a beneficial action in chronic bronchitis by reducing the number of exacerbations. There have been few studies of the effect of NAC (or of any other drug) on general well-being in chronic bronchitis. We used an established psychiatric instrument (General Health Questionnaire; GHQ) and a visual analogue scale (VAS) to measure well-being in a 22-week, placebo-controlled, double-blind, parallel-group study of NAC administered as sustained release tablets 600 mg b.i.d., including during the winter months, to patients with mild chronic bronchitis. One hundred and fifty-three patients were accepted for randomized treatment, 129 finished the study (59 NAC, 70 placebo), and well-being was measured in 105 (46 NAC, 59 placebo). The number of observed exacerbations was unexpectedly low in both groups. The number was lowest in the NAC group, however, the difference did not reach statistical significance in the present study (P=0·08). There were no statistically significant differences between NAC and placebo in subjective symptom scores, FEV1 or FVC. The distribution of GHQ score at baseline was uneven, but NAC was significantly superior to placebo in terms of a favourable effect on GHQ score. GHQ score correlated with the number of exacerbations, and VAS correlated with GHQ score. This study therefore demonstrates the validity of measuring general well-being in patients with mild chronic bronchitis. Future studies of the treatment of chronic bronchitis should use a battery of more specifically adapted instruments which are now becoming available to measure well-being.

References (12)

  • GrassiC et al.

    A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis

    Eur J Clin Pharmacol

    (1976)
  • Long term oral acetylcysteine in chronic bronchitis. A double-blind controlled study

    Eur J Respir Dis

    (1980)
  • BomanG et al.

    Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report on trial organized by the Swedish Society of Pulmonary Disease

    Eur J Respir Dis

    (1983)
  • British Thoracic Society Committee

    Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction

    Thorax

    (1985)
  • RasmussenJB et al.

    Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis

    Eur Respir J

    (1988)
  • VerstraetenJM

    Mucolytic treatment in chronic obstructive pulmonary disease. Double-blind comparative clinical trials with N-acetylcysteine, bromhexine and placebo

    Acta Tuberculosea et Pneumologica Belgica

    (1979)
There are more references available in the full text version of this article.

Cited by (80)

  • The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review

    2017, Heart and Lung: Journal of Acute and Critical Care
    Citation Excerpt :

    However, here, we found that both high-dose and low-dose NAC reduced the proportion of patients with at least one exacerbation. This difference may be due to the inclusion of additional articles6,7 in the present analysis. The other meta-analysis8 analyzed only the frequency of COPD exacerbation as the endpoint.

  • Prevention of Acute Exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline

    2015, Chest
    Citation Excerpt :

    The incidence of adverse effects attributed to the study drug did not differ between the NAC and placebo groups. When examined together, the combined data from these studies240–242 demonstrate a reduction in the rate of exacerbations in COPD associated with the use of NAC compared with placebo (OR, 0.61; 95% CI, 0.37-0.99). Although conclusions are limited by the sample size of the studies assessed, oral NAC is well tolerated and appears to represent a low risk to patients.

  • Treatment of non-cystic fibrosis bronchiectasis

    2011, Archivos de Bronconeumologia
    Citation Excerpt :

    In general, self-administered techniques are recommended for better compliance. The effectiveness of mucolytics has not been clearly demonstrated in patients with bronchiectasis105 or in patients with other pulmonary pathologies.106–108 The Cochrane systematic review,105 based on the paper by Olivieri et al.,109 suggests that bromhexine is the only mucolytic agent that has demonstrated a certain benefit in the treatment of exacerbations of patients with bronchiectasis.

View all citing articles on Scopus
View full text